rituximab biobetter (Huabo Biopharm)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerituximab biobetter (Huabo Biopharm)
Drug Alias Namerituximab biosuperior (Huabo Biopharm)HB-005db
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesHuaBo Biopharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHuaBo Biopharm Co Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A